PEPG
PepGen Inc.- Healthcare
- Biotechnology
- $174M market cap
Forecast run · Oct 29, 2026Upside rank 158 of 3,186
Model Signal
ForecastQ Daily Probabilities
58.8%
63.4%
48.0%
Analyst Consensus
Recommendation2.33/5 Buy
Last price$2.52
Price target$4.00
Implied move+58.7%
Analysts6
ForecastQ Portfolios
PEPG is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.